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Abstract
Background: Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best
genetic barrier to HIV-1 resistance and may be fit for salvage therapy.
Methods: All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight
Italian centres were included in the analysis. The main metabolic data, efficacy parameters and safety data routinely
collected were provided. This observational study is aimed to assess the efficacy of such approach. The primary end-
point was the proportion of subjects achieving or maintaining virologic suppression <50 copies/mL at week 24.
Secondary end points were maintaining virologic suppression in the follow-up (weeks 48 and 96) and safety.
Results: One hundred and thirty subjects were followed for a median of 56 months. Reasons for switching were
simplification (44.6%), viral failure (30%), toxicity (16.9%), non-adherence (4.6%), persistent low-level viremia (3.1%), and
drug-drug interaction (0.8%). At baseline, 118 subjects had documented resistance to 1 to 5 antiretroviral classes while
12 had viral rebound at a time when genotypic tests were not yet available.
Seventeen and 14 subjects took DRV/r and DTG twice daily, respectively. One subject was lost to follow-up, one
discontinued for liver enzymes’ elevation, one died of illicit drug abuse and one of cancer-related complications.
The proportion of subjects with ongoing HIV replication dropped from 40% to 6.1%. Those with undetectable viral load
increased from 38.5% to 76.2%. At week 48, 17.7% had HIV RNA between 1 and 49 copies/mL.
The number of subjects with altered serum glucose, creatinine, ALT, AST, total-, HDL- and LDL-cholesterol, triglycerides
and MDRD <90 mL/min decreased by week 48, while those having MDRD <60 mL/min remained 4.6%. Overall 90/283
baseline laboratory alterations returned to normality.
Conclusions: Switching to DTG plus DRV/r proved to be safe, suppressing viral replication without metabolic impact.
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Background
The present work is the 48-week update of a previously
reported study [1], concerning a retrospective-prospective
follow-up of subjects who had been switched for any
reason to a dual combination of dolutegravir (DTG) plus
darunavir/ritonavir (DRV/r). A randomized clinical trial
comparing the switch to this regimen towards the con-
tinuation of DRV/r plus 2 nucleoside analogues is still
recruiting patients [2]. When we started this strategy of
dual rescue therapy or simplification of more complex res-
cue regimens, the OPTIONS study, the first randomized
trial to utilize a web utility in combination with central-
ized expert opinion to guide the selection of salvage anti-
retroviral therapy was published [3]. The 413 participants
had antiretroviral (ARV) experience or resistance to
nucleoside reverse transcriptase inhibitors (NRTI) and
non-NRTI (NNRTI), were taking a protease inhibitor (PI)-
containing regimen for at least 8 weeks prior to study
entry, and had plasma HIV RNA ≥1000 copies/mL.
Enfuvirtide (ENF), etravirine (ETR), DRV, maraviroc
(MVC), raltegravir (RAL), and tipranavir (TPV) plus rito-
navir booster allowed 20 potential ARV regimens. Fifty-
three subjects had obliged regimen choice due to poor
phenotypic sensitivity score while 360 were randomized to
add or not NRTIs. The resulting regimens were rather
complex, with 3 to 6 drugs and twice-daily dosing, and
generally contained DRV and RAL. The proportion of pa-
tients achieving viral suppression at 48 weeks (<50 HIV-1
RNA copies/mL) was 70.2% and 74.1% for the Omit NRTI
and for the Add NRTI arms, respectively [4]. Prescribers
were generally oriented to prefer simpler regimens.
The combination of elvitegravir/cobicistat/tenofovir
alafenamide/emtricitabine plus 800 mg DRV (two pills
once daily) demonstrated superiority towards the con-
tinuation of baseline therapy in a randomized (2:1),
open-label, switch trial in treatment-experienced viro-
logically suppressed subjects [5]. The baseline regimens
contained in median 5 pills per day and the primary
endpoint was maintaining <50 HIV-1 RNA copies/mL.
In this context some authors were looking forward for
nucleoside-sparing regimens in the long-term care of
HIV infection, welcoming the possible positive contribu-
tion of DTG [6].
The present study reports what the clinical practice
had already realised, aiming for convenience, simplicity,
potency and high genetic barrier, prescribing this com-
bination to several patients and controlling them closely
until viral suppression was achieved.
Methods
All subjects who had started DTG plus DRV/r between
March 1, 2014 and September 30, 2015 were included in
an Italian observational multicenter cohort named Tivista
(Tivicay plus Prezista Observational cohort). After approval
by Ethics Committees (EC) no further enrolment was
allowed. Since the last publication two centres that were
waiting for EC approval joined the group, increasing the
population size. For homogeneity no data were collected
after week 48 (plus 8 weeks’ window as observational stud-
ies do not dictate strict timelines). The follow-up was cen-
sored at November, 30, 2016. Subjects were not required
to be naive to DRV or DTG, but regimens containing both
drugs were not included.
Participating subjects have signed an informed consent
according to local procedures, the study has been ap-
proved by the coordinating centre and by all participat-
ing centres and conducted according to the Good
Clinical Practice (GCP) Guidelines.
The aim of the study is to assess the efficacy of this
approach. The primary end-point was the proportion
of subjects achieving or maintaining virologic sup-
pression <50 copies/mL at week 24. Secondary end
points were maintaining virologic suppression in the
follow-up (weeks 48 and 96) and safety, as proportion
of drop-outs for any reason and grade 3–4 adverse
events.
Safety data and laboratory standards
In this update it was decided to document the impact of
the switch on some routine safety analyses. Investigators
retrospectively reported to the coordinating center serum
glucose, alanine aminotransferase (ALT), aspartate amino-
transferase (AST), total cholesterol (TC), high density
lipoprotein (HDL-C), low density lipoprotein (LDL-C)
and triglycerides (TG). The estimated glomerular filtration
rate (e-GFR) was calculated at baseline and at follow-up
according to the Modification of Diet in Renal Disease
(MDRD) equation [7]. Plasma viral suppression status was
classified as harbouring ≥50 HIV-1 RNA copies/mL, or
detectable below 50 copies/mL, or undetectable (no virus
detected, NVD = 0 copies/mL).
Viremia was measured depending on centers with
Abbot HIV-1 RT-PCR, threshold 37 copies, COBAS
TaqMan HIV-1 test, threshold 20 copies, and Single
Copy Assay. TruGene™ was used for resistance testing,
validated on the Stanford Algorithm, and cumulative
data was considered. Data were collected from electronic
or hand-written patients’ case record forms, according to
each centre’s organization and sent as pre-specified excel
files. Available data from routine therapeutic monitoring
of darunavir and dolutegravir trough plasma concentra-
tion were analysed.
For the toxicity analyses the Common Terminology
Criteria for Adverse Events (CTCAE, Version 4.03, June
14, 2010) was considered [8]. Adverse clinical events and
deaths were reported to the local Ethics Committees and
authorities as required by the law.
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Statistical analysis
The statistical analysis was limited to routine parameters
(median, mean and standard error) and to the paired t-
test for the comparison between the baseline and 48-
week metabolic and immunologic values. The virologic
response is reported as the number of patients in each
viral suppression category and as the median and inter-
quartile range of log10 copies/mL in those who do not
reach suppression at each time point. The other analyses
consider the on-treatment population. The sample size
was obtained from the participants’ adhesion.
Results
One hundred and thirty subjects were followed for a me-
dian of 56 months, mean 64 months. The median age
was 52 years, females were 25.4% and non-Caucasians
8.9%. The median baseline CD4+ T-cell count was 526/
mmc (IQR 329–718). Fifty-nine subjects had been ex-
posed to INSTIs and all had been exposed to PIs.
Eighty-one had darunavir in their pre-switch regimen
and one had dolutegravir. The main risk factor for
acquiring HIV was being male homosexual, 48.5%
(n = 63), followed by drug abuse, 26.9% (n = 35) and
heterosexual intercourse, 24.6% (n = 32). Reasons that
led to the switch were simplification, 44.6% (n = 56),
viral failure 30% (n = 39) toxicity 16.9% (n = 22, of
which 11 for osteopoenia/osteoporosis, 3 each for
lipodystrophy and cardiovascular problems, 2 for renal
toxicity and one each for gastrointestinal toxicity, dia-
betes and creatine kinase elevation), non-adherence,
4.6% (n = 6), persistent low-level viremia, 3.1% (n = 4),
and drug-drug interaction, 0.8% (n = 1). The algorithm
of the study population is represented in Fig. 1.
At baseline 118 subjects had documented resistance to
1 to 5 ARV classes. For the remaining 12 patients, viral
failure was not accompanied by a genotypic test. Twenty-
three subjects (17.7%) had never experienced virologic
failure but had transmitted drug resistance mutations.
One hundred and sixteen patients (89.2%) had NRTI
resistance-associated mutations (RAMs) at baseline, 98
(75.4%) had NNRTI RAMs, 91 (70%) had PI RAMs and
12 (10.6%) had integrase strand transfer inhibitors
(INSTI) RAMs (See Table 1).
Twenty subjects had reduced baseline sensitivity to
darunavir (Stanford median score 15, range 15–40), and
12 had reduced sensitivity to INSTIs (Stanford median
score 10, range 10–25) but none rebounded. None de-
veloped new drug resistance mutations during the study.
Of those subjects who had resistance to 3–4 drug clas-
ses (n = 70), 35 were not failing at baseline, but rather
simplified from raltegravir and boosted darunavir-based
three- (n = 31) or four-drugs regimens (n = 9).
One hundred and thirteen have started the combination
of DRV 800 mg plus RTV 100 mg plus DTG 50 mg every
24 h, 3 DRV 600 mg plus RTV 100 mg every 12 h and 14
DRV 600 mg plus RTV 100 mg plus DTG 50 mg every
12 h. All of those who were on BID therapy had active
HIV-1 replication at baseline (range 5.46–6.16 log10 HIV-
1 RNA copies/mL). All of them suppressed viremia to <50
copies/mL during the follow-up.
Between week 24 and 48 one subject was lost to
follow-up, one interrupted the regimen for liver
Fig. 1 Algorithm of the study population. DTG = dolutegravir; DRV/r = darunavir boosted with ritonavir; AST = aspartate aminotransferase;
ALT = alanine aminotransferase
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enzymes’ elevation, one died of illicit drug abuse and
one of cancer-related complications.
The proportion of subjects harboring active HIV repli-
cation dropped from 40% at baseline to 6.1% by week
48, while those who had NVD at real-time polymerase
chain reaction (RT-PCR) increased from 38.5% to 76.2%.
Overall, at baseline 78 subjects had <50 HIV-1 RNA
copies/mL (60%) and this proportion increased at week
48 to 90,8% (n = 118) At week 48, 19 subjects (14,6%)
had HIV RNA between 1 and 49 copies/mL and eight
subjects (6,1%) had ≥50 HIV-1 RNA copies/mL. Of the
latter, 3 had a slow but constant decay from median
baseline 5.12 to 2.30 log10 HIV-1 RNA copies/mL, 3 had
at least three-class drug resistance with a Stanford DRV
score > 60 and median viral decay from 4.39 to 1.75
log10 HIV-1 RNA copies/mL, and 2 had dropped out of
therapy 4 and 7 days before blood sampling. Considering
separately two populations, those who started with active
HIV replication (≥ 50 copies/mL) and those who started
with 0–49 copies/mL, at week 48 the success rate was
88.5% in those who had started with active replication,
as 3 with high baseline viral load and 3 with extensive
baseline resistance, had still very low but detectable
viremia, while in those who started with 0–49 copies/
mL the success rate was 97.4% as in this group two
subjects were not on therapy on the sampling day, as de-
scribed above. Of interest, both were in the subgroup
starting with 1–49 copies/mL, as some authors suggest
that this low but persistent viremia may sometime hide
adherence problems. The mean viral load in this popula-
tion at week 48 was 1.89 log10 copies/mL (range 1.70–
2.57, Fig. 2). The CD4+ T-cell absolute count and
proportion increased by 27 cells/mm3, +5%, not reaching
statistical significance.
A single-point pharmacokinetic analysis in a subgroup
of 32 subjects confirmed the safety of the association:
DTG median Ctrough was 579 ng/mL (range 275–5036),
while DRV median Ctrough was 3007 ng/mL (range 678–
8053) and no values were found to be below the safety
threshold. Five subjects were taking DRV 600 mg twice
daily and had Cmin above the threshold for resistant
strains, and three were taking DTG twice daily.
Table 1 Baseline HIV-1 drug resistance mutations in the study population
Primary resistance mutations (Wensing, 2017) are underlined
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The proportion of subjects having any metabolic
alterations at baseline decreased for serum glucose,
creatinine, MDRD <90 mL/min, ALT, AST, total-,
HDL- and LDL-cholesterol and triglycerides. The pro-
portion of subjects having MDRD <60 remained
stable at 4.6%. Overall 84/175 (48%) baseline labora-
tory alterations returned to normality. Considering
each parameter in the whole population, none varied
significantly (Fig. 3).
In particular, the median variation in serum cre-
atinine was −0,03 and the eGFR decrease on average
by 2.66 mL/min. None of the subjects who had al-
tered serum creatinine at baseline showed progres-
sion and 6 out of 8 improved, having discontinued
tenofovir.
Overall this strategy yielded mean savings for €
169,428.00 considering the whole population, the obser-
vation period and the dropouts. The figure was gener-
ated only from the cost of the previous and current
antiretroviral regimen.
Discussion
While awaiting the results of the randomized DUALIS
study [2], our data suggest that the combination of DTG
plus DRV/r may be considered reliable in salvage or sim-
plification of salvage regimens. The pharmacokinetic
interaction between the two drugs [9] did not seem to im-
pact neither causing subtherapeutic Cmin in the subjects
tested nor leaving space for plasma HIV-1 RNA rebound
in any subject. In particular, 70% of our patients would
not have been suitable for the combination of DTG plus
atazanavir, which has a favourable interaction profile [10]
due to baseline resistance to the latter and it should be
said that clinical experience with this combination is still
limited though promising. Moreover, we have not re-
ported significant neurological side effects, as suggested
by Hoffman et al. [11] Possible reasons may be the com-
bination, which does not include abacavir, the fact that
many of our patients had received the indication to take
the drug in the morning and the relatively small number
of other at risk subjects (15 elderly and 33 women).
Fig. 2 Virologic and immunologic response. a n. of patients by HIV-1 RNA, copies/mL; b HIV-1 replication decay in the population with ongoing viral
replication, log10 copes/mL; c CD4+ T-lymphocytes/mmc; d CD4+ T-lymphocytes, %. eGFR = estimated Glomerular Filtration Rate, calculated on the
Modified Diet for Renal Disease (MDRD) score; AST = aspartate aminotrasferase; ALT = alanine aminotrasferase; TC = total cholesterol; HDL-C = HDL
cholesterol; LDL-C = LDL cholesterol
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The study limitations include poor patient selection (the
only two inclusion criteria were being HIV-1 antibody
positive and having started DTG plus DRV/r by the end of
September 2015), leading to the inclusion of a heteroge-
neous population, made out of failures and simplification,
once- and twice-daily regimens, adherent and poorly
adherent subjects and subjects harbouring treatment-
resistant and treatment-sensitive strains. The set of meta-
bolic parameters furthermore reflects standard follow-up
data shared by centres and does not include bone density
measures nor inflammatory markers.
Conclusions
Switching to DTG plus DRV/r provided a simple and safe
rescue regimen to all subjects, controlling viral replication
in a high proportion of patients. The metabolic impact
was favourable in a proportion of subjects who had base-
line alterations, while no significant modifications were
observed in mean and median values when also normal
baseline values were included.
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